Advanced Hepatocellular Carcinoma
Conditions
Brief summary
The study is being conducted to evaluate the efficacy and safety of SHR-1210 plus FOLFOX4 in subjects with advanced HCC who have never received prior systemic treatment compared to placebo plus FOLFOX4. The primary study hyposis is that Camrelizumab combined with FOLFOX4 treatment can improve Overall Survival when compared with placebo in combination with FOLFOX4 Regimen.
Interventions
DRUGSHR-1210
Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
DRUGFOLFOX4
Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
DRUGPlacebo
Subjects receive placebo of SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Has not received prior systemic treatment for their advanced/metastatic HCC. Has measurable disease according to RECIST v1.1. ECOG Performance Status of 0 or 1. Child-Pugh Class A or B with 7 points. Life Expectancy of at least 12 weeks. HBV DNA\<500 IU/ml. Adequate organ function： Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug.
Exclusion criteria
Known fibrolamellar HCC, Prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured. Known or occurrence of central nervous system (CNS) metastases. Ascites with clinical symptoms. Known or evidence of GI hemorrhage within the past 6 months. Known or occurrence of hemorrhage/ thrombus. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias. Grade III\ IV cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF\<50%. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure \> 150mmHg, diastolic blood pressure \> 90 mmHg). History of hepatic encephalopathy. Known history of human immunodeficiency virus (HIV) infection. Active infection or an unexplained fever \> 38.5°C during screening visits. Prior or planning to organ transplantation including liver transplantation. Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity. Proteinuria≥ 2+ and 24 hours total urine protein \> 1.0 g. Active known, or suspected autoimmune disease. Subjects with a condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Any loco-regional therapy to liver (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks prior to study. Known history of hypersensitivity to monoclonal antibodies or any components of the study drugs. Pregnant or breast-feeding women. According to the investigator, other conditions that may lead to stop the research.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Up to approximately 3 years | OS was defined as the time from randomization to death due to any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression (TTP) per RECIST 1.1 in all participants | Up to approximately 3 years | — |
| Duration of Response (DoR) per RECIST 1.1 in all participants | Up to approximately 3 years | — |
| Disease Control Rate (DCR) per RECIST 1.1 in all participants | Up to approximately 3 years | — |
| Objective Response Rate (ORR) per RECIST 1.1 in all participants | Up to approximately 6 months | ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1. |
| AE | Up to approximately 3 years | — |
| Overall Survival (OS) rate at 9 months and 12 months | Up to approximately 9 months and 12 months | — |
| Progression-free Survival (PFS) per RECIST 1.1 in all participants | Up to approximately 3 years | — |
Countries
China
Contacts
Primary ContactLinna Wang, MD
Outcome results
None listed